UK-101

• UNSPSC Description:

  UK-101 is a potent and selective immunoproteasome β1i (LMP2) inhibitor with an IC50 value of 104 nM, displays 144- and 10-fold selectivity over β1c (IC50=15 μM) and β5 subunit (IC50=1 μM), respectivey[1]. UK-101 induces cell apoptosis and can be used for the study of prostate cancer[2].

• Target Antigen:

  Apoptosis; Proteasome

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/uk-101.html

• Purity:

  99.58

• Solubility:

  DMSO : 7.3 mg/mL (ultrasonic;warming)

• Smiles:

  O=C([C@]1(CO1)CO[Si](C)(C)C(C)(C)C)[C@H](CC(C)C)NC([C@H](C)NC(CCCCCC)=O)=O

• Molecular Weight:

  484.74

• References & Citations:

  [1]de Bruin G, et al. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. J Med Chem. 2014 Jul 24;57(14):6197-209.|[2]Wehenkel M, et al. A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer. 2012 Jun 26;107(1):53-62.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1000313-40-5